Clinical trials: Functional Diarrhea
Irritable Bowel Syndrome
Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide
A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.
- Trial name
- NCT01678781
- Where
- 24 sites in China, Egypt and 2 more
- Volunteers
- 607 people
- Sponsor
- Abbott
Diarrhea, Upper Respiratory Infections
Children Immune Functions(2)
To investigate the effect of milk-based formulas on infections and immune functions in healthy children.
- Trial name
- NCT01731392
- Testing
- Milk with Bifidobacteria, Milk with non replicating lactobacilli
- Where
- Indonesia
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Diarrhea
Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.
This study aims to assess elemental impurities level after dministration of dioctahedral smectite in subjects with functional diarrhea or irritable bowel syndrome with predominant diarrhea.
- Trial name
- NCT05816681
- Testing
- DWJ1230, DWB2001
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome
Diarrhea Predominant Irritable Bowel Syndrome in Females
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS) The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women for the treatment of diarrhea-predominant…
- Trial name
- NCT00461526
- Testing
- crofelemer
- Where
- 43 sites in United States
- Volunteers
- 240 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts.
- Trial name
- BALANCE (NCT07519395)
- Testing
- Camlipixant
- Where
- 114 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation
GOS to Reduce Symptom Severity in IBS
IBS is a highly prevalent bowel disorder, characterized by recurrent abdominal pain during bowel movements or a change in bowel habits.
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed
- Trial name
- EGIS (NCT05157061)
- Testing
- Galacto-oligosaccharides (GOS), Maltodextrine
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 153 people
- Sponsor
- Clasado
Irritable Bowel Syndrome With Diarrhea (IBS-D)
G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea
A randomized, double-blind, placebo-controlled pilot study in patients with IBS-D according to Rome IV criteria evaluating the clinical efficacy and safety of oral administration of 2g G-PUR® tid compared to placebo in a cohort…
- Trial name
- NCT04138186
- Testing
- 2.0g G-PUR®, oral administration
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Glock Health, Science and Research GmbH
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.
- Trial name
- NCT00394173
- Testing
- DNK333
- Where
- 43 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Novartis
Irritable Bowel Syndrome With Diarrhea
Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.
- Trial name
- NCT01177410
- Testing
- Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
- Where
- 20 sites in United States
- Volunteers
- 148 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
- Trial name
- NCT04880876
- Testing
- 25mg Eluxadoline, 100mg Eluxadoline
- Where
- 6 sites in United States
- Volunteers
- 124 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome
Safety and Efficacy of a Probiotic Supplement in IBS-D
This study aims to assess the safety and efficacy of a single probiotic strain on symptom severity in adults with diarrhea-predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- IBIS (NCT05754177)
- Testing
- Probiotic
- Where
- Slovenia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Irritable Bowel Syndrome
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189696
- Testing
- YM060
- Where
- 4 sites in Japan
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Fecal Calprotectin Collection Protocol
The primary objective is to obtain stool samples from subjects diagnosed with , and displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study.
- Conditions
- Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease
- Trial name
- CALFE (NCT03143517)
- Testing
- Stool collection
- Where
- 13 sites in United States
- Volunteers
- 240 people
- Sponsor
- DiaSorin Inc.
IBS - Irritable Bowel Syndrome
Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)
The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and depression) as well as general quality of life in…
- Trial name
- NCT05509725
- Testing
- Probiotic formulation
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Congenital Sucrase-isomaltase Deficiency (CSID)
Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)
Congenital sucrose-isomaltase deficiency (CSID) is a rare, genetic disease in which mutations in the sucrose-isomaltase (SI) gene cause digestion problems of sucrose resulting in diarrhea and abdominal pain.
- Trial name
- CSID GPS (NCT01914003)
- Where
- 19 sites in United States
- Volunteers
- 53 people
- Sponsor
- QOL Medical, LLC
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01274000
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Astellas Pharma Inc